Technological progress towards sustainable development

The purpose of this paper is twofold. First, to present an analysis of a comprehensive set of global energy scenarios that has been undertaken to identify key energy technologies for achieving sustainable development. Secondly, to describe tools that could aid policy makers using insights in the dynamics of technological progress to promote the development of promising technologies throughresearch and development (R&D) and procurement. As an operational working definition of sustainable development we use the following four criteria: (1) Economic growth sustains throughout the whole time horizon; (2) socio-economic inequity among world regions is reduced "significantly" during this century; (3) reserves-to-production (R/P) ratios of exhaustible primary energy carriers do not decrease substantially from today's values; and (4) short- to medium-term environmental impacts (e.g., acidification) are reduced towards meeting critical loads and carbon emissions at the end of the century are below today's levels. Applying these criteria in an analysis of a representative set of global economy-energy-environment scenarios shows that in sustainable-development scenarios, hydrogen fuel cells and solar photovoltaic cells emerge as key technologies in the long run. Natural gas technologies, in particular fuel cells and combined-cycle power plants, could provide for an efficient medium-term transition to these key technologies. The question then becomes which policies can promote the development of these technologies. We think that an important tool to tackle this question is provided by an improved concept of technological learning. According to that concept, technological progress, expressed as specific technology cost, is a regular function of not only cumulative installed capacity but also of R&D expenditures. This tool can assist in determining how much money should be spent for which energy technology on procurement (capacity expansion) and how much money for R&D. The results of first model runs aiming at eventually formulating policy guidance are presented

Aviram-Ratner rectifying mechanism for DNA base pair sequencing through graphene nanogaps

We demonstrate that biological molecules such as Watson-Crick DNA base pairs can behave as biological Aviram-Ratner electrical rectifiers because of the spatial separation and weak hydrogen bonding between the nucleobases. We have performed a parallel computational implementation of the ab-initio non-equilibrium Green's function (NEGF) theory to determine the electrical response of graphene---base-pair---graphene junctions. The results show an asymmetric (rectifying) current-voltage response for the Cytosine-Guanine base pair adsorbed on a graphene nanogap. In sharp contrast we find a symmetric response for the Thymine-Adenine case. We propose applying the asymmetry of the current-voltage response as a sensing criterion to the technological challenge of rapid DNA sequencing via graphene nanogaps

Agronomic Performance and Nutraceutical Quality of a Tomato Germplasm Line Selected under Organic Production System

Organic tomato production is increasing worldwide, thus making necessary the development of varieties adapted to this farming system. It is now well known that the implementation of local tomato plant breeding programs for organic farming is required to increase the performance of varieties in this typology of cultivation regime. In this research, the agronomic performance, nutraceutical contents, and radical scavenging activity of a tomato germplasm line (OSTGL), selected under organically grown conditions, were evaluated for two consecutive years (2018 and 2019) in comparison with the variety ‘Rio Grande’, frequently grown organically in Tunisia. Carotenoids, phenolics, vitamin C, and radical scavenging capacity were assayed spectrophotometrically, while tocopherols were analyzed by HPLC. All data were not affected by year-to-year variability. The OSTGL line showed significantly higher marketable yield, total phenol, flavonoid, vitamin C, α-tocopherol and γ-tocopherol contents, along with radical scavenging activity. The OSTGL red-ripe berries also showed comparable values for average weight, soluble solids, pH, titratable acidity, firmness and coloration, as well as lycopene and β-carotene contents. This open pollinated tomato germplasm line demonstrated to be an effective sustainable variety for improving fruit yield, agronomic, and nutraceutical characteristics under an organic management system

Carbon lock-in through capital stock inertia associated with weak near-term climate policies

Stringent long-term climate targets necessitate a limit on cumulative emissions in this century for which sufficient policy signals are lacking. Using nine energy-economy models, we explore how policies pursued during the next two decades impact long-term transformation pathways towards stringent long-term climate targets. Less stringent near-term policies (i.e., those with larger emissions) consume more of the long-term cumulative emissions budget in the 2010-2030 period, which increases the likelihood of overshooting the budget and the urgency of reducing GHG emissions after 2030. Furthermore, the larger near-term GHG emissions associated with less stringent policies are generated primarily by additional coal-based electricity generation. Therefore, to be successful in meeting the long-term target despite near-term emissions reductions that are weaker than those implied by cost-optimal mitigation pathways, models must prematurely retire significant coal capacity while rapidly ramping up low-carbon technologies between 2030 and 2050 and remove large quantities of CO2 from the atmosphere in the latter half of the century. While increased energy efficiency lowers mitigation costs considerably, even with weak near-term policies, it does not substantially reduce the short-term reliance on coal electricity. However, increased energy efficiency does allow the energy system more flexibility in mitigating emissions and, thus, facilitates the post-2030 transition

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.

BackgroundHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies. Anthracyclines, such as doxorubicin, are an effective treatment for HER2-positive breast cancer, particularly when administered in combination with trastuzumab - however, doxorubicin-related cardiotoxicity has limited its use. Many patients are therefore never treated with anthracyclines, even upon disease progression, despite the potential for benefit. MM-302 is a novel, HER2-targeted antibody-liposomal doxorubicin conjugate that specifically targets HER2-overexpressing cells. Preclinical and Phase 1 data suggest that MM-302, as a monotherapy or in combination with trastuzumab, could be effective for managing previously treated, anthracycline-naïve, HER2-positive breast cancer, without the cardiotoxicity observed with free doxorubicin formulations.Methods/designHERMIONE is an open-label, multicenter, randomized (1:1) Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice (gemcitabine, capecitabine, or vinorelbine) plus trastuzumab planned to enroll 250 anthracycline-naïve patients with locally advanced/metastatic HER2-positive breast cancer. Key inclusion criteria are: previous treatment with trastuzumab (with or without pertuzumab) in any setting; refractory or intolerant to pertuzumab (refractory to pertuzumab defined as progression in the locally advanced or metastatic setting, or disease recurrence during or within 12 months of completing pertuzumab-containing neoadjuvant and/or adjuvant therapy); and disease progression on, or intolerant to, ado-trastuzumab emtansine for locally advanced or metastatic disease. The trial is currently being conducted at sites in the USA, Canada, and Western Europe. Treatment will be administered in 21-day cycles, and will be continued until disease progression or unacceptable toxicity. The primary endpoint is independently assessed progression-free survival (PFS). Tumor response will be assessed every 6 weeks, and defined according to RECIST v1.1. Secondary endpoints include investigator-assessed PFS, overall survival (OS), OS rates at 6 months and 1 year, objective response rates, safety and tolerability, quality of life, and the pharmacokinetic profile of MM-302 plus trastuzumab.DiscussionThe HERMIONE study will evaluate the efficacy and safety of MM-302 plus trastuzumab in patients with refractory HER2-positive advanced/metastatic breast cancer for whom there are no standard of care therapies with a proven survival advantage.Trial registrationClinicaltrials.gov identifier: NCT02213744 . Registration date: 06AUG2014

"They should have this in every court." Evaluation of the NSW Women’s Refuge Movement Women's Family Law Support Service (WFLSS)

This is an evaluation of the first support service in Australia for women attending the Family Courts. The WFLSS is a partnership between the NSW Women's Refuge Movement and the Family Court of Australia. This evaluation provides the views of women and court staff about the service

The impact of near-term climate policy choices on technology and emission transition pathways

This paper explores the implications of delays (to 2030) in implementing optimal policies for long-term transition pathways to limit climate forcing to 450 ppm CO2e on the basis of the AMPERE Work Package 2 model comparison study. The paper highlights the critical importance of the period 2030-2050 for ambitious mitigation strategies. In this period, the most rapid shift to low greenhouse gas emitting technology occurs. In the delayed response emission mitigation scenarios, an even faster transition rate in this period is required to compensate for the additional emissions before 2030. Our physical deployment measures indicate that the availability of CCS technology could play a critical role in facilitating the attainment of ambitious mitigation goals. Without CCS, deployment of other mitigation technologies would become extremely high in the 2030-2050 period. Yet the presence of CCS greatly alleviates the challenges to the transition particularly after the delayed climate policies, lowering the risk that the long-term goal becomes unattainable. The results also highlight the important role of bioenergy with CO2 capture and storage (BECCS), which facilitates energy production with negative carbon emissions. If BECCS is available, transition pathways exceed the emission budget in the mid-term, removing the excess with BECCS in the long term. Excluding either BE or CCS from the technology portfolio implies that emission reductions need to take place much earlier